T
he outcome of experimental infection in inbred strains of mice infected with Leishmania major is profoundly influenced by the nature of the CD4 + T cell response to the disease. Disease resistance and susceptibility appear to depend on the cytokine profile secreted by particular subsets of CD4 + lymphocytes. In mouse strains that develop small localized lesions that ultimately resolve, exemplified by the C57B1/6 mouse, resistance is preferentially associated with the presence of IFN-7-producing CD4 + cells of the Thl subset (1) . In mice that develop a progressive and ultimately fatal infection, characterized by the BALB/c mouse, susceptibility is preferentially associated with the presence of IL-4-producing T cells of the Th2 subset (1) . It has been directly demonstrated by adoptive transfer of specific Thl and Th2 cell lines that these T cell subsets mediate disease resistance or susceptibility (2) . A causal relationship between cytokine production and disease outcome is further suggested by the observation that anti-IL-4 treatment attenuates disease in susceptible mice (3), while anti-IFN-7 antibody treatment induces susceptibility in otherwise resistant mice (4) . The observation, however, that administration of IFN-3' to BALB/c mice after the initiation of infection does not modify the progression of disease (3, 5) suggests that factors other than IFN-y alone are necessary for the development of a durable Thl response.
IL-12, also known as natural killer cell stimulating factor (NKSF) and cytotoxic lymphocyte maturation factor (CLMF), is a heterodimeric cytokine produced by monocytes and B cells (6) (7) (8) . It displays a potent array of biological activities affecting NK and T cells. These biological activities include the ability to enhance proliferation of NK and T cells, to induce production of IFN-% and to enhance NK and T cell cytolytic activity (6) (7) (8) (9) (10) . Of particular interest to the leishmanial model is the observation that IL-12 can promote the development of Thl cells (11a) .
In this study, we examine the effects of recombinant mufine (rm)IL-12 administration on the immune response to cutaneous leishmaniasis in highly susceptible BALB/c mice. Conversely, we also examine the effects of anti-rmlL-12 antibody therapy in resistant C57B1/6 mice. We demonstrate that IL-12 plays a critical role in the development of a protective Thl immune response and in controlling the progression of chronic disseminating leishmaniasis in these animal models.
Materials and Methods
Leishmania. L. major, National Institutes of Health Seidman strain (WHOM/SN/74 Seidman), was used in these investigations (12) . Amastigotes were propagated in mice by serial infection and obtained from infected footpad tissue as described (13) .
Animals and Infection. Female BALB/cJ (H-2a; amastignte and lymphocyte donors) and C57B1/6 (H-2b; lymphocyte donors) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were infected subcutaneously into each hind footpad with a 0.05-ml suspension of 2 x 10 s tissue-derived amastigotes (13) in 0.15 M NaC1.
NKSF/IL.12. Serum-free culture supernatant was collected and purified from Chinese hamster ovary cells stably transfected with amplified cDNAs for the p40 and p35 subunits of raiL-12. SDS-PAGE analysis revealed this preparation to consist predominantly of mlb12 heterodimeric (95 %) with a small amount of monomeric p40 subunit (5 % ). rml-L-12 was stored in 500-/~g aliquots of calciumand magnesium-free modified Dulbecco's PBS at -80~ until used. The specific activity was '~7.8 x 106 U/rag. 1 U is defined relative to a human IL-12 standard RB 012892 in a PHA blast proliferation assay. 1 U is approximately equal to the amount that yields half-maximal stimulation. Endotoxin levels as measured by the Limulus amebocyte lysate assay did not exceed 0.5-0.9 EU/mg. In the second study BALB/c mice (n ,= 10 per treatment group) were administered rmlL-12 intraperitoneally in the following manner. Immediately after a challenge with amastigotes in the hind footpads, one group received 0.33/xg/d rmlb12 for a consecutive 5 d/wk for 5 wk, or alternatively another group received saline alone in a similar manner. An additional group received 1.0 ~g/d traiL,12 for a consecutive 5 d for the first week of infection only, while with another group treatment with 1.0/~g/d rmlb12 was delayed until the second week of infection, where it was given for a consecutive 5 d/wk and continued for a total of 5 wk. Representative animals from each group at selected time intervals were killed and footpad parasite burdens were quantified by published methods (13) .
In
Neutralizing Rabbit Anti-rmll_,12 Antibody. Female New Zealand white rabbits were immunized subcutaneously with 50/~g of rmlb12 in adjuvant bimonthly. An immune Ig fraction from antisera pooled from one rabbit (031302, anti-IL-12) was obtained by binding to protein A-agarose column (Repligen Corp., Cambridge, MA) according to established procedures (14, 15) using a FPLC chromatography system (Pharmacia Fine Chemicals, Piscataway, NJ). Purified antibody was stored at -80~ until needed. This anti-l-b12 preparation is not known to react with any other cytokines other than Ib12 (our unpublished observations).
In Vivo Anti-II.,12 Treatment. After a challenge with amastigotes in the hind footpads, C57B1/6 mice (n = 8 per treatment group) were treated with either anti-IL-12 antibody or normal rabbit Ig (I-5006; Sigma Chemical Co., St. Louis, MO) by intraperitoneal injection of 200/~g of either material commencing on the day of challenge and continued every other day for 25 d. At selected time intervals parasite burdens were quantified as described above.
Lymph Node Lymphocytes and Lympholeine-containing Culture Supernatants. Lymph node lymphocytes were obtained from draining popliteal lymph nodes of Leishmania-infected or normal mice as described (13) . Lymphokine-containing culture supernatants were prepared by published methods (16) . Briefly, cultures of lymph node cells (106/ml) in RPMI supplemented with 2.5% FCS serum (Hyclone Laboratories, Logan, UT) were incubated at 37~ with either culture-derived promastigotes, tissue-derived amastigotes, anti-CD3 mAb (145-2Cli, hamster IgG, 10/xg/ml; PharMingen, San Diego, CA), or left untreated. The cell-free conditioned medium from lymph node cell cocultures was harvested after 48 h and stored at -80~ until analyzed for activity.
Immunoassays for IFN-'y and 11.:4. ELISAs using mAbs specific for mlFN-',/(Genzyme Corp., Cambridge, MA) or mlL-4 (Endogen Inc., Boston, MA) that have been previously described (17, 18) were used to quantify the amount of IFN-3' or I1.,4 present in culture supernatants of lymph node cells cultured in vitro. A standard curve for each assay was generated with known concentrations of mlFN-3' or mlb4 in protein-stabilized supplemented media.
Results

Treatment of BALB/c Mice with rralL-2 Affects Progression of Lesion Development in Footpads Infected with Leishmania.
To assess whether administration of rmIL-12 could influence leishmanial parasite growth in BALB/c mice (susceptible to cutaneous hishmaniasis), footpad thickness was monitored in infected mice treated by intraperitoneal injection with saline, 0.11 or 0.33/~g rmIL-12 once daily (qd), for a consecutive 5 d/wk for 5 wk. Footpad thickness steadily increased in salinetreated animals during the 5-wk course. In contrast, at both doses of traiL-12, the increase in footpad thickness was reduced. By the fifth week of infection, animals treated with 0.11 or 0.33/~g traiL-12 had footpad thicknesses of 4.23 _+ 0.25 and 3.07 _+ 0.21 mm (n = 5, mean +_ SD), respectively. Footpad thickness in saline-treated animals was 5.60 _+ 0.10 ram. These observations suggested that traiL-12 induced a reduction in parasite burden. Histological examination of infected footpad tissue confirmed this conclusion (data not shown).
Administration of rmlL-12 to BALB/c Mice during the First Week of Infection Is Sufficient to Induce Resistance to Leishmania.
To determine the temporal sequence of when rmlL-12 therapy was necessary to prevent lesion development, mice were infected by footpad injection and then treated with 1.0/~g rmlL-12 qd for a consecutive 5 d immediately after infection, or treated with 1.0/~g qd beginning 1 wk after infection. Mice given delayed therapy were administered rmIL-12 for a consecutive 5 d/wk for a total of 5 wk. As controls, additional groups of infected mice or uninfected mice received 0.33 #g rmlL-12 as described above, and an infected group received saline.
Parasite burdens in infected mice were determined by microscopic examination of stained amastigote suspensions derived from infected footpad tissue (Table 1) . At 5 wk postinfection, parasite burden was reduced fivefold in mice treated continuously with 0.33 #g/d rmlL-12 when compared with saline-treated mice. More significantly, parasite reduction in mice treated with 1.0/~g rmlL-12 for the first week of infection was 15-fold compared with saline controls. In contrast, parasite reduction was less than twofold in mice where treatment began 1 wk after infection.
Treatment of mice for a consecutive 5 d postinfection was sufficient to prevent the development of footpad lesions. This protective effect of therapy was still apparent at 10 wk postinfection ( Table 1 ), suggesting that the induced antileishmanial effects were sustained. Treatment starting I wk after parasite challenge reduced the rate of lesion progression compared with saline-treated animals. These mice, however, remained susceptible so that by 8 wk lesion size approached that oh- * 106/ml lymph node cells were stimulated with 10 s amastigotes/ml or left untreated for 48 h in supplemented media with 2.5% FCS. Cell-free supernatants were then collected and stored at -80~ before being assayed.
served in saline-treated controls at 4-5 wk of infection, necessitating that the mice be killed. Administration of rmlL-12 to uninfected mice did not induce an increase in footpad swelling. IFN-'y production by lymph node cells of mice treated with traiL-12 was 10-fold greater than that produced by salinetreated mice (Table 2 ). In contrast, cells from rmlL-12-treated mice produced fivefold less IL-4 than cells from saline controis. Semiquantitative PCR analysis of RNA from popliteal lymph node cells demonstrated that in vivo IFN-7 RNA levels in infected animals were increased by rmlL-12 treatment (10-fold increase compared with untreated controls; data not shown).
Administration of rmlL-12 at the Time of Leishmania Infection in BALB/c Mice Alters Cytokine
In addition, we observed that rmlL-12 treatment for 5 d postinfection appeared sufficient to initiate a protective Thl response early in infection (Table 1) . To assess the cytokine profile produced under these conditions, popliteal lymph node cells were collected 5 wk postinfection from these treated mice and assayed as described above. In vitro IFN-~ produc- tion from mice treated with 1.0/xg/d rmlL-12 for a consecutive 5 d immediately after infection was 10-fold greater than that of cells from saline-treated mice. Concomitantly, there was a 10-fold reduction in the level of IL-4 produced by these cells compared with saline controls (Table 2) . Accompanying these changes we also observed a decrease in the relative percentage of CD4 + T cells of the Th2 subset in the draining popliteal lymph nodes of treated mice as determined by immunophenotyping using anti-CD45R isotype antibody MB23G2/15Cll (19, data not shown).
Treatment of C57B1/6 Mice with Rabbit anti-rmlL-12 antibody
Abrogates Natural Resistance to L. major. The observation above that rmlL-12 induces resistance in susceptible BALB/c mice suggested that host production of IL-12 might be responsible for protection in a resistant mouse strain. To test this hypothesis, mice from a resistant mouse strain, C57B1/6, were administered polyclonal rabbit anti-rmlL-12 antiserum beginning at the time of infection with L. major. Infected footpad tissues of C57B1/6 mice administered normal rabbit Ig had minimal swelling by 3 wk postinfection that returned to nearly baseline by 6 wk. In contrast, mice treated with anti-rmlL-12 antiserum developed large nonhealing lesions. By 4 wk postinfection, these footpads were twice as large as that of control animals and nearly as large as those of susceptible BALB/c mice. Examination of parasite suspensions derived from footpad tissue at 5 wk postinfection confirmed that footpad swelling was associated with increased parasite burden (>70% increase compared with untreated ELISAs using mAbs specific for mlFN3~ were used. Cells were derived from popliteal lymph nodes of C57B1/6 mice infected with L. major amastigotes for 1-2 wk. * Mice were treated intraperitoneally on the day of infection with 200 /~g normal rabbit Ig or rabbit anti-rmlL-12 qd and every other day thereafter for 25 d. Lymph node cells were stimulated with amastigotes, promastigotes, anti-CD3 mAb, or left untreated for 48 h in supplemented media. Supernatants were collected and stored at -80~ before analysis. controls; 4.9 x 104 _+ 1.9 x 103 amastigotes/mg tissue and 1.3 x 103 _+ 3.6 x 103 amastigotes/mg tissue [n = 3, mean +_ SD], respectively).
The increased disease susceptibility suggested that administration of anti-rmlL-12 antisera to C57B1/6 mice resulted in the inhibition of their normal Thl response to infection. To test this hypothesis, we measured in vitro the capacity of popliteal lymph node cells to produce IFN-% At 1-2 wk postinfection, there was a >50% decrease in IFN-~/production by lymph node cells from anti-rmlL-12-treated mice when compared with cells from control antisera-treated animals (Table 3 ). These observations taken together with those above demonstrate that the presence of IL-12 at the time of infection is crucial in determining whether a Thl or Th2 response develops, and in the control of progressive disease. . Additional cytokines are also produced by both these subsets. These subsets are thought to arise from a common precursor after stimulation via their TCRs (21) . The mechanisms favoring the development of ThI and Th2 cels and which factors or cytokines determine this differentiation are not well defined.
In mouse models of cutaneous leishmaniasis, a spectrum of disease ranging from self-healing cutaneous ulceration to progressive visceral dissemination occurs in association with distinct lymphokine responses. In particular, resolution of cutaneous disease requires the expansion of spedfic Thl cells that produce IFN-y, while exacerbation of infection requires the expansion of specific Th2 cells that produce IL-4 (1, 2). In this report, we provide evidence that IL-12 has a major role in influencing the development of a protective Thl immune response in L. major infection. We show that treatment with traiL-12 in BALB/c mice reverses their susceptibility to infection (Table 1 ). This alteration in susceptibility is due to a shift in the T cell response from a predominant Th2-to a Thl-type response (Table 2) . Accompanying changes in IFN-3' and IL-4 levels produced by draining lymph node cells upon in vitro restimulation from these mice confirm that the IL-12-treated mice produce a more Thl-like response.
Two sets of data pinpoint the time most critical for the presence of IL-12 in the resolution of L. major disease. When IL-12 is administered only during the first week of infection, we observe resolution of infection. These data suggest that clearance of parasites from cutaneous tissues of BALB/c mice early after infection is influenced by IL-12. When treatment was delayed until the second week of infection, the animals were not able to heal the infection although disease progression was delayed. Thus, the presence of IL-12 during the initial parasite host-cell interactions in the first week of infection is dearly critical for resolution of disease. Further evidence in support of the role of IL-12 in the generation of a protective Thl response is the demonstration that the administra-tion of anti-IL-12 antibody in vivo exacerbates disease in normally resistant C57B1/6 mice. Depletion of IL-12 profoundly affects the ability of these mice to dear the parasite inoculum from cutaneous tissues and is accompanied by a shift in IFN-3/and IL-4 production, rendering a more Th2-1ike response than in normal rabbit Ig-treated mice (Table 3) . Combined with the ability of IL-12 to augment Thl responses in BALB/c mice, these data in C57B1/6 mice indicate that IL-12 is critical for the development of a Thl response.
Earlier studies examining the role of Thl and Th2 cells in the immune response to Leishmania provided evidence demonstrating the key role that IFN-7 plays in modulating the Thl response to leishmanial infections. In particular, neutralizing antibodies to IFN-3' were shown to be capable of abrogating protective immunity in genetically resistant mice 4, 5). In addition, Thl cells mediating immunity to infection produce IFN-% whose expression and secretion directly correlates with the reduction in parasite burdens in infected resistant mice (1, 2) .
Paradoxically, however, the administration of IFN-7 itself after the initiation of infection, although leading to a dday in the generation of lesions, ultimately provides no long-term control of infection (3, 5) . These observations suggest that factors in addition to IFN-3 ~ were necessary for the development of a sustained Thl response. We believe the evidence provided here strongly suggests that IL-12 is a critical factor in initially determining a Thl response. Moreover, the ability of IL-12 to directly induce IFN-7 production in both NK and T cells (6, 7, 22) , in addition to synergizing with other physiological IFN-7 inducers, is consistent with IL-12 having a key role as a immunopotentiating agent in generating a Thl response. Our preliminary observations have also shown that the administration of anti-IFN-7 antibody to infected BALB/c mice treated with traiL-12 abrogates their ability to initiate a protective immune response (data not shown). These data suggest that IL-12 may be influencing the early clearance of parasites by initiating a protective Thl response, as well as by the induction of IFN-7.
The murine model of cutaneous leishmaniasis provides an excellent system in which to examine the role CD4 + T cells and their respective cytokines play in the resolution of pathogenesis of infectious diseases. We have shown that IL-12 plays a crucial role in initiating a Thl cell response and is essential for inducing a protective host immune response. As CD4 + subsets become better defined in other disease models, these observations will be useful in designing strategies for the development of vaccines and immunotherapy against other infectious pathogens.
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